Arbutus Biopharma Corporation ABUS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $179.13M+16,943% | $1.05M+98.7% | $529K-95.1% | $10.74M+509% | $1.76M+12.1% | ||
| $4.12M-17.7% | $5.01M-13.4% | $5.78M+5.1% | $5.5M-38.6% | $8.96M+1.7% | ||
| $5.89M+59.6% | $3.69M+21.2% | $3.04M-8.5% | $3.33M-42.9% | $5.83M+23.8% | ||
| $11K— | —— | $11K0.0% | $11K-96.7% | $330K— | ||
| $0-100% | $303K+209% | $98K-99.2% | $12.4M+0.2% | $12.37M+12,924% | ||
| $10.22M+61.1% | $6.34M-31.0% | $9.19M-0.7% | $9.25M-66.3% | $27.46M+77.1% | ||
| $10.22M+61.1% | $6.34M-31.0% | $9.19M-0.7% | $9.25M-66.3% | $27.46M+77.1% | ||
| $168.91M+3,293% | -$5.29M+38.9% | -$8.66M-682% | $1.49M+106% | -$25.7M-84.4% | ||
| 94.3%+598pp | -503.3%+1,134pp | -1,636.9%-1,651pp | 13.9%+1,471pp | -1,456.9%-572pp | ||
| $17K-5.6% | $18K-21.7% | $23K-17.9% | $28K0.0% | $28K-6.7% | ||
| $815K-7.1% | $877K-7.9% | $952K-8.6% | $1.04M-12.9% | $1.2M-18.2% | ||
| $787K-48.7% | $1.53M+67.3% | $917K-11.4% | $1.04M-11.8% | $1.17M-16.3% | ||
| $169.7M+4,618% | -$3.76M+51.5% | -$7.74M-407% | $2.52M+110% | -$24.53M-95.7% | ||
| 94.7%+452pp | -357.4%+1,106pp | -1,463.5%-1,487pp | 23.5%+1,414pp | -1,390.4%-594pp | ||
| $0.87+8,800% | -$0.01+75.0% | -$0.04-500% | $0.01+108% | -$0.13-85.7% | ||
| $0.88+8,900% | -$0.01+75.0% | -$0.04-500% | $0.01+108% | -$0.13-85.7% | ||
| 195.2M+1.9% | 191.6M-0.1% | 191.8M-0.3% | 192.4M+0.9% | 190.7M+2.7% | ||
| 193.8M+1.1% | 191.6M-0.1% | 191.8M+0.1% | 191.6M+0.4% | 190.7M+2.7% | ||
| $209K— | —— | $268K+3.1% | $260K-13.0% | $299K— | ||
| —— | -$457.5K0.0% | -$457.5K0.0% | -$457.5K0.0% | -$457.5K-170% | ||
| $169.6M+4,653% | -$3.73M+51.5% | -$7.68M-407% | $2.5M+110% | -$24.56M-95.3% | ||
| -$97K— | —— | $58K+376% | -$21K+32.3% | -$31K— | ||
| -$11K-1,200% | $1K+108% | -$12K-157% | $21K+425% | $4K+112% | ||
| $168.91M+3,293% | -$5.29M+38.9% | -$8.66M-682% | $1.49M+106% | -$25.7M-84.4% | ||
| $168.92M+3,349% | -$5.2M+39.9% | -$8.65M-677% | $1.5M+106% | -$25.37M-86.7% | ||
| $168.92M+3,349% | -$5.2M+39.9% | -$8.65M-677% | $1.5M+106% | -$25.37M-86.7% | ||
| 94.3%+589pp | -494.7%+1,140pp | -1,634.8%-1,649pp | 14%+1,452pp | -1,438.2%-575pp | ||
| $168.91M+3,293% | -$5.29M+38.9% | -$8.66M-682% | $1.49M+106% | -$25.7M-84.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arbutus Biopharma Corporation's revenue?
- Arbutus Biopharma Corporation (ABUS) generated $191.4M in revenue over the trailing twelve months, up 2889.9% year over year.
- Is Arbutus Biopharma Corporation profitable?
- Arbutus Biopharma Corporation reported $160.7M in net income over the trailing twelve months, a 84.0% net margin.
- What is Arbutus Biopharma Corporation's earnings per share?
- Arbutus Biopharma Corporation's diluted EPS over the trailing twelve months is $0.83.
- Where does Arbutus Biopharma Corporation's income statement data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
